Glucose conjugation of anti-HIV-1 oligonucleotides containing unmethylated CpG motifs reduces their immunostimulatory activity

© 2015 Wiley-VCH Verlag GmbH & Co. KGaA. Antisense oligodeoxynucleotides (ODNs) are short synthetic DNA polymers complementary to a target RNA sequence. They are commonly designed to halt a biological event, such as translation or splicing. ODNs are potentially useful therapeutic agents for the...

Descripción completa

Detalles Bibliográficos
Autores: Reyes-Darias, José Antonio, Sánchez-Luque, Francisco J., Morales, Juan Carlos, Pérez-Rentero, Sonia, Eritja Casadellà, Ramón, Berzal-Herranz, Alfredo
Tipo de recurso: artículo
Fecha de publicación:2015
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/113463
Acceso en línea:http://hdl.handle.net/10261/113463
Access Level:acceso abierto
Palabra clave:Glucose DNA oligonucleotides
HIV-1 inhibition
Immune response reduction
Conjugated oligonucleotides
Descripción
Sumario:© 2015 Wiley-VCH Verlag GmbH & Co. KGaA. Antisense oligodeoxynucleotides (ODNs) are short synthetic DNA polymers complementary to a target RNA sequence. They are commonly designed to halt a biological event, such as translation or splicing. ODNs are potentially useful therapeutic agents for the treatment of different human diseases. Carbohydrate-ODN conjugates have been reported to improve the cell-specific delivery of ODNs through receptor mediated endocytosis. We tested the anti-HIV activity and biochemical properties of the 5′-end glucose-conjugated GEM 91 ODN targeting the initiation codon of the gag gene of HIV-1 RNA in cell-based assays. The conjugation of a glucose residue significantly reduces the immunostimulatory effect without diminishing its potent anti-HIV-1 activity. No significant effects were observed in either ODN stability in serum, in vitro degradation of antisense DNA-RNA hybrids by RNase H, cell toxicity, cellular uptake and ability to interfere with genomic HIV-1 dimerisation.